Impact News +++ Market movers: Virgin Galactic, Soleno Therapeutics, Medicus Pharma... (Proactive Investors) +++ VIRGIN GALACTIC Aktie -3,81%

CHUGAI PHARMACEUTICAL ADR Aktie

>CHUGAI PHARMA Performance

1 Woche: +11,2%

1 Monat: -12,5%

3 Monate: +6,3%

6 Monate: +25,9%

1 Jahr: +17,8%

laufendes Jahr: +9,2%

>CHUGAI PHARMACEUTICAL ADR Aktie

Name:

CHUGAI PHARMACEUTICAL ADR

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US1712691039 / A12ABF

Symbol/ Ticker:

CUP0 (Frankfurt)

Kürzel:

FRA:CUP0, ETR:CUP0, CUP0:GR

Index:

Webseite:

https://www.chugai-pharm...

Profil:

Chugai Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry, focusing on the research, development, manufacturing, and sale of innovative medicines. The primary purpose of Chugai Pharmaceutical is to address the unmet medical..
>Volltext..

Marktkapitalisierung:

80330.24 Mio. EUR

Unternehmenswert:

75057.65 Mio. EUR

Umsatz:

7282.53 Mio. EUR

EBITDA:

3912.45 Mio. EUR

Nettogewinn:

2510.44 Mio. EUR

Gewinn je Aktie:

0.76 EUR

Schulden:

142.1 Mio. EUR

Liquide Mittel:

2357.79 Mio. EUR

Operativer Cashflow:

2274.96 Mio. EUR

Bargeldquote:

2.38

Umsatzwachstum:

8.87%

Gewinnwachstum:

13.47%

Dividende je Aktie:

1.13 EUR

Dividendenrendite:

2.63%

Dividendenschätzung:

1.74%

Div. Historie:

29.12.25 - 0.39666834€
30.06.25 - 0.36479327€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

CHUGAI PHARMACEUTICAL ADR, CHUGAI PHARMACEUTICAL, CHUGAI PHARMA, CHUGAI PHARMACEUTICALS

Letzte Datenerhebung:

07.04.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 3291.43 Mio. St.

Frei handelbar: 100%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: 7872

Umsatz/Mitarb.: 0.93 Mio. EUR

Analysten:

Analystenrating: No rating

Kursziel: -

Bewertung:

KGV: 32.83

KGV lG: -

KUV: 11.46

KBV: 7.36

PEG-Ratio: 2.47

EV/EBITDA: 19.18

Rentabilität:

Bruttomarge: 71.05%

Gewinnmarge: 34.47%

Operative Marge: 49.92%

Managementeffizenz:

Gesamtkaprendite: 19.45%

Eigenkaprendite: 23.16%

>Peer Group

Gesundheit, Diabetes- & Adipositas- Behandlung, Onkologie/ Krebs- Behandlung, Nierenerkrankungen & -behandlung

>CHUGAI PHARMA Chart & Kurs - Frankfurt

>CHUGAI PHARMA News

30.03.26 - 09:36

Mitsubishi Electric Announces Director Candidates (Business Wire)

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that the candidates for Directors, who will be proposed for election at the Ordinary General Meeting of Shareholders scheduled in June 2026, were elected at the company's Nomination Committee meeting held earlier today. Director Candidates (current positions) Tatsuro Kosaka (Director (Senior Advisor, CHUGAI PHARMACEUTICAL CO., LTD.)) Hiroyuki Yanagi (Director) Masako Egawa (Director (Chancellor, Seikei Gakuen)) Haruka Matsuyama (Director (Attorney-at-law (Partner, Hibiya Park Law Offices))) Kunihito Minakawa (Director) Peter D. Pedersen (Director (Executive Director, NELIS, a corporation engaging in specified non-profit activities)) Mieko Nakabayashi (Professor, Waseda University) [new candidate] Kei Uruma (Director; Representative Executive Officer, President & CEO) Atsuhiro Yabu (Director) Noriyuki Takazawa (Director; Representative Executive Officer, Senior Vice President; CSO (in charge of Corporate Strategic Planni...

29.01.26 - 21:36	Chugai Pharmaceutical: Rekordgewinne im Geschäftsjahr 2025, doch Aktie gibt nach (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

29.01.26 - 10:33	Chugai Pharmaceutical reports FY results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.01.26 - 10:00	Chugai Pharma FY25 Results Climb, Sees Growth In FY26 Core Profit, Revenues (AFX)
	TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) reported Thursday higher profit and revenues in fiscal 2025. The company further announced year-end dividends, and lower fiscal 2026 di......

22.12.25 - 09:54	Chugai Secures Regulatory Nod For Tecentriq In Thymic Carcinoma (AFX)
	TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Monday announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Tecentriq Intravenous Infusion for an addit......

25.11.25 - 12:36	Chugai Reports Positive Data From TEIEN Study Of Port Delivery System With Ranibizumab In NAMD & DME (AFX)
	TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Tuesday reported positive results from its phase I/II TEIEN study evaluating the Port Delivery System with Ranibizumab (PDS) in pati......

25.11.25 - 12:24	Chugai Pharmaceutical Teams With Biomy For Development Of AI-based Cancer Pathology Program (AFX)
	TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCY.PK), Tuesday announced a Memorandum of Understanding with Biomy, Inc., a provider of innovative services for pharmaceutical companies, for ......

06.11.25 - 22:33	Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update (GlobeNewswire EN)
	– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics –...

27.10.25 - 11:18	Chugai Pharmaceutical: Gewinn übertrifft Prognosen in Q3 2025, doch Umsatzenttäuschung belastet die Aktie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

24.10.25 - 12:54	Chugai Pharmaceutical 9-month Net Income Rises (AFX)
	BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Chugai Pharmaceutical Co. reported, on a IFRS basis, nine month net income of 305.6 billion yen, up 3.3% from a year ago. Revenue was 911.6 billion yen, up 5.0......

24.10.25 - 10:03	Renalys Pharma to be Acquired by Chugai Pharmaceutical (PR Newswire)
	TOKYO, Oct. 24, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Tokyo; Representative Director Chaiman & CEO; BT Slingsby; "Renalys") and Chugai Pharmaceutical Co., Ltd. (Headquarters: Tokyo; President & CEO: Osamu Okuda; "Chugai") today announced a definitive stock purchase......

17.10.25 - 13:33

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing (GlobeNewswire EN)

SAN JOSE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a Collaboration and License Agreement with Chugai Pharmaceutical Co., Ltd. ("Chugai") for the development and commercialization of an oral product consisting of Rani's oral delivery technology, the RaniPill®, and Chugai's rare disease antibody in development....

24.07.25 - 12:09	Chugai Pharmaceutical reports Q2 results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

24.04.25 - 19:45	Chugai Pharmaceutical Co. (CHGCY) Upgraded to Buy: Here′s Why (Zacks)
	Chugai Pharmaceutical Co. (CHGCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

18.04.25 - 05:48	Weight-loss pill orforglipron shines in study, boosting Lilly and Chugai (Japan Times)
	Eli Lilly's orforglipron pill, licensed from Chugai Pharmaceutical, could reshape the booming weight-loss drug market, early data shows....

31.03.25 - 08:42

Mitsubishi Electric Announces Director Candidates (Business Wire)

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that the candidates for Directors, who will be proposed for election at the Ordinary General Meeting of Shareholders scheduled in June 2025, were elected at the company's Nomination Committee meeting held earlier today. 1. Director Candidates (current positions) Tatsuro Kosaka (Director (Senior Advisor, CHUGAI PHARMACEUTICAL CO., LTD.)) Hiroyuki Yanagi (Director (Adviser, Yamaha Motor Co., Ltd.)) Masako Egawa (Director (Chancellor, Seikei Gakuen)) Haruka Matsuyama (Director (Attorney-at-law (Partner, Hibiya Park Law Offices))) Kunihito Minakawa (Director (Financial Services Agency Certified Public Accountants and Auditing Oversight Board Commissioner)) Peter D. Pedersen (Director (Executive Director, NELIS, a corporation engaging in specified non-profit activities)) Kei Uruma (Director; Representative Executive Officer, President & CEO) Atsuhiro Yabu (Director) Noriyuki Takazawa (Senior Vice President; Infrastructure Bu...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Unsere Gesellschaft hat viel mehr Vertrauen in Dinge, die sich nicht ändern. - Univ.-Prof. Mag. Dr. Markus Hengstschläger

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram